| Status : Published | Published On : Apr, 2024 | Report Code : VRHC1282 | Industry : Healthcare | Available Format :
|
Page : 192 |
Global Genomic Cancer Panel And Profiling Market – Analysis and Forecast (2025-2030)
Industry Insight By Tissue Testing Type (Solid and Liquid), By Cancer Panel Type (Single-Gene and Multiple-Gene), By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer and Other), By Application (Clinical and Research), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC) and Others), By End-User (Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes and Other) and By Geography (North America, Europe, Asia-Pacific, Latin America and Rest of the World)
Industry Overview
The Global Genomic Cancer Panel And Profiling Market is expected to reach USD 25.64 billion by 2030 from USD 9.20 billion in 2023. The Global Genomic Cancer Panel And Profiling Market is expected to grow at a CAGR of 8.33% during the forecast period 2025-2030.
The advancements in genomic research and an increasing focus on precision medicine within the field of oncology is driving the growth in this market. Genomic cancer panels and profiling are highly used to detect cancer by studying the genetic details of tumors before symptoms appear. The ability of the genomic cancer panels and profiling is to provide comprehensive genetic insights, facilitating early detection and the formulation of personalized treatment plans. The revolutionary potential of these technologies hold in reshaping cancer management is the main growth driver of the Genomic Cancer Panel And Profiling Market. These panels offer a more accurate means of identifying specific genetic alterations, which enable healthcare professionals to alter intervention accordingly.
Increasing demand for early cancer detection while treating cancer patients, has shown a significant growth in the Global Genomic Cancer Panel And Profiling Market. The changing lifestyle of people has increased the cancer risk, due to which there is an increased popularity and appreciation of liquid biopsy tests leading to the growth of the Global Genomic Cancer Panel And Profiling Market.
Impact of the Market
The Global Genomic Cancer Panel And Profiling Market has made an remarkable impact. Doctors choose treatments using effective genetic information. Finding cancer early has also made easier to treat and beat it in a specific time period. Personalized treatment is playing a major role in the treatment. Research and Testing new treatments has made easy to treat the cancer. Genomic profiling assists in developing appropriate follow-up plans and adjusting treatments. The progress in genomic technologies have led to the cost of genomic profiling. A large patient population is accessible to benefit from personalized cancer treatment.
Market Segmentation
Insight by Tissue Testing
Based on tissue testing type , The Global Genomic Cancer Panel And Profiling Market is segmented into Solid and liquid tissue testing. Using liquid samples for testing, rather than traditional methods, is expected to become more common and important in understanding and treating cancer and is dominating the market
Insight by Cancer Panel Type
Based on cancer panel type, The Global Genomic Cancer Panel And Profiling Market is bifurcated into single-gene panel and multi-gene panel. Multi-gene panel segment dominated the global genomic cancer panel and profiling market, as these panels, examine multiple genes simultaneously, understand and analyze cancer at the genomic level on a global scale.
Insight by Cancer Type
On the basis of cancer type, The Global Genomic Cancer Panel And Profiling Market is segregated into lung cancer, breast cancer, colon cancer, prostate cancer and other cancers. Breast cancer dominated the global genomic cancer panel and profiling market, as it is one of the most common types of cancer globally.
Insight by Application Type
On the basis of application type, The Global Genomic Cancer Panel And Profiling Market is classified into Clinical and Research. Genomic cancer panels provide critical information that helps Clinicians make more informed decisions about the most effective treatments for individual patients due to which clinical segment dominated the global genomic cancer panel and profiling market.
Insight by Technology Type
On the basis of Technology type, The Global Genomic Cancer Panel And Profiling Market is classified into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC) and Others. Next-Generation Sequencing (NGS) segment dominated the global genomic cancer panel and profiling market. It offers comprehensive, cost-effective, and efficient genomic analysis in the field of cancer genomics.
Insight by End-User Type
On the basis of End-User type, The Global Genomic Cancer Panel And Profiling Market is classified into Hospitals, Clinical and Diagnostic Laboratories, Research and Academic Institutes and Other End Users. Hospitals segment dominated the global genomic cancer panel and profiling market. Hospitals often have multidisciplinary teams of healthcare professionals, including oncologists, pathologists, and genetic counselors.
Global Genomic Cancer Panel And Profiling Market Report Coverage
|
Report Metric |
Details |
|
Historical Period |
2018 - 2023 |
|
Base Year Considered |
2024 |
|
Forecast Period |
2025 - 2030 |
|
Market Size in 2023 |
U.S.D. 9.20 Billion |
|
Revenue Forecast in 2030 |
U.S.D. 25.64 Billion |
|
Growth Rate |
8.33% |
|
Segments Covered in the Report |
By Tissue Testing Type, By Cancer Panel Type, By Cancer Type, By Application, By Technology and By End-User |
|
Report Scope |
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling |
|
Regions Covered in the Report |
North America, Europe, Asia-Pacific, Latin America and Rest of the World |
Industry Dynamics
Growth Drivers
Rising need for cancer profiling in developed countries drives the demand for genomic panels and profiling tests. Larger proportion of individuals is in the elderly age group in developed countries. Cancer occurrence tends to increase with age. This trend drives a steady demand for cancer treatment and related healthcare services. Genomic cancer panels contribute to this by helping in identifying genetic markers associated with early-stage cancers. Early detection allows for timely interventions, improving treatment outcomes and reducing the overall load of the disease.
Restraints
Poor reimbursement circumstances and lack of standard regulations are the major restraints, faced by the genomic cancer panel and profiling market. Reimbursement reductions in the genomic cancer panel and profiling market have significant implications for both healthcare providers and patients. Lack of access to the testing samples, improper conditions of its storage facilities, and rise in usage of immunotherapy are the major factors that are widely restraining the overall market growth.
Geographic Overview
- North America
- Europe
- Asia Pacific (APAC)
- Latin America
- Rest of the World
Based on region, North America dominated the global genomic cancer panel and profiling market in terms of market size. However, the Asia-Pacific region, is encompassing numerous emerging economies during the forecast period.
Key Players Covered in the Report
Key players of The Global Genomic Cancer Panel And Profiling Market are Agilent Technologies, Inc., Burning Rock DX, Myriad Genetics, ARUP Laboratories, Danaher Corporation (Integrated DNA Technologies, Inc.), Caris Life Sciences, Thermo Fisher Scientific, Inc., Exact Sciences Corporation, Fulgent Genetics, F. Hoffmann-La Roche Ltd., Genecast Biotechnology Co. Ltd., Illumina, Inc., Invitae Corporation.
Recent Developments by Key Players
Recently, Agilent Technologies, announced the launch of the Agilent ProteoAnalyzer system to boost capabilities in protein analysis. The Agilent ProteoAnalyzer system is a new automated parallel capillary electrophoresis system for protein analysis that brings more efficiency, versatility and reliability in protein QC workflows by automating the separation, data processing and simplifying sample preparation steps. In this way it analyzes complex protein mixtures seamlessly without compromising the accuracy of the results. Agilent is expected to gain strong momentum across the pharma, biotech, food analysis and academia sectors on the back of its latest move, as the ProteoAnalyzer system can help companies reduce training and labor costs.
In recent times, Myriad Genetics collaborated with Memorial Sloan Kettering Cancer Center (MSK) to study the use of Myriad's minimal residual disease (MRD) testing platform in predicting breast cancer treatment response. The platform is a tumor-informed high-definition assay that monitors circulating tumor DNA (ctDNA) levels via whole-genome sequencing. The partners will be studying treatment response prediction in patients with metastatic breast cancer treated with CDK4/6 inhibitors, as well as investigating the association of MRD testing with chemotherapy treatment response.
The Genomic Cancer Panel And Profiling Market report offers a comprehensive market segmentation analysis along with estimation for the forecast period 2025–2030.
Segments Covered in the Report
- By Tissue Testing Type
- Solid
- Liquid
- By Cancer Panel Type
- Single-gene
- Multi-gene
- By Cancer Type
- Lung
- Breast
- Colon
- Prostate
- Other
- By Application Type
- Clinical
- Research
- By Technology Type
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescence In-Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Others
- By End-User Type
- Hospitals
- Clinical and Diagnostic Laboratories
- Research and Academic Institutes
- Others
Region Covered in the Report
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia-Pacific (APAC)
- China
- Japan
- India
- Latin America
- Brazil
- Mexico
- Other Countries
- Rest of the World
- Saudi Arabia
- South Africa
- U.A.E
- Other Countries
.png "Global Genomic Cancer Panel and Profiling Market Size and Market Analysis")
Frequently Asked Questions
Purchase Options
Latest Report
Research Methodology
- Desk Research / Pilot Interviews
- Build Market Size Model
- Research and Analysis
- Final Deliverabvle
Connect With Our Sales Team
- Toll-Free: 1 888 253 3960
- Phone: +91 9960 288 381
- Email: enquiry@vynzresearch.com
Genomic Cancer Panel And Profiling Market